Highlights Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 13/02/2026			5-day change	1st Jan Change
238,000.00 ^KRW	-0.21%		+4.62%	+31.49%

02-05	CVS Health to drop Amgen and Lilly's bone disease treatments from some drug lists (February 5)	RE
01-30	Celltrion Launches Autoimmune Drug Aptozma in Europe	MT

Highlights

01-14	Celltrion Presents Innovative Drug Pipeline and U.S. Manufacturing and R&D Expansion Strategy At the 44Th Annual J.P. Morgan Healthcare Conference	CI
01-06	Abpro Holdings, Inc. and Celltrion, Inc. Announce U.S. FDA IND Clearance for Lead Multispecific Antibody Cancer Candidate ABP-102 / CT-P72	CI
01-02	Health Care Up on Anti-Obesity Drug Sales Outlook - Health Care Roundup	DJ
01-02	Celltrion, Inc. acquired Biopharmaceutical Manufacturing Facility in the United States from Eli Lilly and Company (NYSE : LLY).	CI
01-02	Celltrion Shares Rally on U.S. Contract, Earnings Outlook	DJ
12-21	Samsung Biologics to buy US drug production facility from GSK for $280 million	RE
12-18	Celltrion, Inc. Receives Positive CHMP Opinion for SteQeyma (Uustekinumab Biosimilar) Autoinjector	CI
12-15	Abpro Holdings, Inc. and Celltrion, Inc. Announces Submission of an IND Application to Initiate a Phase 1 Clinical Trial of T Cell Engager ABP-102/CT-P72 for HER2-Positive Cancers	CI
12-10	Celltrion, Inc. announces Annual dividend	CI
12-03	Celltrion Announces U.S. FDA Approval of 300mg strength of OMLYCLO®?	CI
11-28	Celltrion, Inc. Receives Health Canada Approval for Eydenzelt®?, a Biosimilar Confirming Eylea®? (aflibercept 2Mg)	CI
11-26	Celltrion Announces Publication of Post-Hoc Analysis of Liberty-Cd Study of Zymfentra®? (Infliximab-Dyyb)	CI
11-18	Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo?? 300Mg	CI
11-18	Celltrion, Inc Announces European Commission Grants Approval of Remsima?? IV Liquid Formulation, World's First Liquid Formulation of IV Infliximab	CI
11-14	Celltrion, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-07	Prime Medicine Q3 net loss narrows	RE
30/10/25	U.S. FDA Grants Interchangeability Designations to Celltrion's Denosumab Biosimilar, STOBOCLO (denosumab-bmwo) and OSENVELT (denosumab-bmwo)	CI
22/10/25	Celltrion to sell 746 million won worth of own shares	RE
21/10/25	Celltrion's Q3 Operating Income, Sales Rise	MT
20/10/25	Wellscare Signs A Memorandum of Understanding with Celltrion Canada	CI
17/10/25	Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on September 17, 2025.	CI
17/10/25	FDA Approves Expanded Pediatric Indications for YUFLYMA®? (Adalimumab-Aaty) and Unbranded Adalimumab-AatY in the United States	CI
14/10/25	Celltrion, Inc.'s Equity Buyback announced on September 17, 2025, has closed with 572,932 shares, representing 0.26% for KRW 100,000.03 million.	CI
10/10/25	Celltrion Receives U.S. FDA Approval for EYDENZELT®? (aflibercept-boav), Biosimilar Confirming EYLEA®? (aflibercept)	CI
06/10/25	Celltrion, Inc. Presents Positive Real-World Data on Switching from Intravenous (Iv) to Subcutaneous (Sc) Injectioniximab At Ueg Week 2025 Meet the Expert Sessions	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Celltrion, Inc.

Equities

A068270

KR7068270008

Biotechnology & Medical Research

Highlights

Filters